Press Releases - 2008

12/17/2008
Anthony R. Campbell Elected to Columbia Laboratories Board of Directors
LIVINGSTON, NJ – December 17, 2008 - Columbia Laboratories, Inc. (Nasdaq: CBRX) announced today that as of December 16, its Board of Directors elected Anthony R. Campbell as a director of the Company. Mr. Campbell is a manager and senior analyst for Dorset Management Corporation and a member of Knott Partners Management, LLC.
11/10/2008
Largest Study Demonstrates Comparable Pregnancy Outcomes Using Vaginal Gel Versus Injectable Progesterone, with Frozen Embryos from Donar Eggs
The largest retrospective analysis to date, conducted at Boston IVF, a Harvard Medical School affiliate, is the first to demonstrate that there were no significant differences in pregnancy outcomes for recipients of previously frozen embryos from donor oocytes (eggs), in patients using vaginally-administered progesterone gel (CRINONE® 8%) versus progesterone injected intramuscularly (IM).
11/6/2008
Columbia Laboratories Reports Third Quarter 2008 Financial Results
Columbia Laboratories, Inc. (Nasdaq: CBRX) today reported financial results for the three- and nine-month periods ended September 30, 2008.
10/30/2008
Columbia Laboratories to Discuss Third Quarter Financial Results on November 6, 2008 Conference Call
Columbia Laboratories, Inc. (Nasdaq: CBRX) will hold a conference call on November 6, 2008 to discuss financial results of the third quarter and nine-month period ended September 30, 2008. Robert S. Mills, president and chief executive officer, and James A. Meer, senior vice president, chief financial officer and treasurer of Columbia Laboratories, will host the call
10/23/2008
Columbia Laboratories Enter Collaborative Agreement With the National Institutes of Health (NIH)
Perinatology Research Branch of the NICHD and Columbia Laboratories to Collaborate in the Phase III PREGNANT Short Cervix Study
10/22/2008
Columbia Laboratories to Present at the Oppenheimer & Co. 19TH Annual Healthcare Conference on November 3, 2008
Columbia Laboratories, Inc. (Nasdaq: CBRX) announced today that Robert S. Mills, president and chief executive officer of Columbia Laboratories, Inc. will present at the upcoming Oppenheimer & Co. 19th Annual Healthcare Conference.
10/8/2008
Columbia Laboratories Reiterates 2008 Year-end Revenue Guidance
Columbia Laboratories, Inc. (Nasdaq: CBRX) today announced that, based on preliminary financial projections, the Company reiterates its previously announced 2008 year-end revenue guidance. On March 11, 2008, Columbia indicated that it expects to achieve 2008 revenues in the range of $35 to $40 million.
9/29/2008
Columbia Laboratories Reports Results from Phase II Clinical Trial of Vaginally-administered Lidocaine for Dysmenorrhea
Columbia Laboratories, Inc. (Nasdaq: CBRX) today announced results from its Phase II study of vaginally-administered lidocaine, which the Company is investigating for the prevention and treatment of dysmenorrhea. No treatment currently exists to prevent dysmenorrhea.
8/26/2008
Columbia Laboratories Closes Registered Direct Common Stock Offering
Columbia Laboratories, Inc. (Nasdaq: CBRX) has raised approximately $4.7 million in gross proceeds to the Company through the sale of approximately 1.3 million shares of its common stock at a price of $3.50 per share in a registered direct offering. Net proceeds are expected to be approximately $4.1 million after offering-related fees and expenses.
8/7/2008
Columbia Laboratories Reports Second Quarter 2008 Financial Results
Columbia Laboratories, Inc. (Nasdaq: CBRX) today reported financial results for the three- and six-month periods ended June 30, 2008.
7/30/2008
Columbia Laboratories to Discuss Second Quarter Financial Results on August 7, 2008 Conference Call
Columbia Laboratories, Inc. (Nasdaq: CBRX) will hold a conference call on August 7, 2008 to discuss financial results of the second quarter and six-month period ended June 30, 2008. Robert S. Mills, president and chief executive officer, and James A. Meer, senior vice president, chief financial officer and treasurer of Columbia Laboratories, will host the call.
6/24/2008
Columbia Laboratories Set to Join Russel 3000® Index
Columbia Laboratories, Inc. (Nasdaq: CBRX) is set to join the broad-market Russell 3000® Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on June 27, 2008, according to a preliminary list of additions posted June 13, 2008 on www.russell.com.
5/8/2008
Columbia Laboratories Reports First Quarter 2008 Financial Results
Columbia Laboratories, Inc. (Nasdaq: CBRX) today reported financial results for the three-month period ended March 31, 2008.
5/2/2008
Columbia Laboratories to Discuss First Quarter Finanacial Results on May 8, 2008 Conference Call
Columbia Laboratories, Inc. (NASDAQ: CBRX) will hold a conference call on May 8, 2008 to discuss financial results of the first quarter and three-month period ended March 31, 2008. Robert S. Mills, president and chief executive officer, and James A. Meer, senior vice president, chief financial officer and treasurer of Columbia Laboratories, will host the call.
3/18/2008
Columbia Laboratories to Restate Earnings Due to Adjustments for Interest Expense
Columbia Laboratories, Inc. (NASDAQ: CBRX) today announced it will restate its financial statements for the fiscal years ended December 31, 2005 and December 31, 2006, and for the first three quarters of fiscal 2007. The Company will request a 15-day extension from the Securities and Exchange Commission to file its annual report on Form 10-K for the year ended December 31, 2007.
3/5/2008
Columbia Laboratories to Discuss Fourth Quarter and Year End 2007 Financial Results on March 11, 2008 Conference Call
Columbia Laboratories, Inc. (NASDAQ: CBRX) will hold a conference call on March 11, 2008 to discuss financial results of the three- and twelve-months period ended December 31, 2007. Robert S. Mills, president and chief executive officer, and James A. Meer, senior vice president, chief financial officer and treasurer of Columbia Laboratories, will host the call.
2/13/2008
New Website Explaining Role of Progesterone Support in Pregnancy and Fertility Launched By Columbia Laboratories, Inc.
Columbia Laboratories, Inc. (NASDAQ:CBRX) today announced the launch of a new website (www.crinoneusa.com) to educate women about the role of progesterone in fertility and pregnancy. This new website provides helpful information on the role of progesterone, the ‘pregnancy hormone,’ in preparing a woman’s body for pregnancy and helping her to maintain a pregnancy. In addition, this website features clinical data on progesterone vaginal gel for healthcare providers.
2/11/2008
Columbia Laboratories to Present at the ROTH Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California on February 20, 2008
LIVINGSTON, NJ— February 11, 2008 — Robert S. Mills, president and chief executive officer of Columbia Laboratories, Inc., (NASDAQ: CBRX) will present at the ROTH Capital Partners 20th Annual OC Growth Stock Conference.
2/5/2008
Columbia Laboratories Receives IRB Approval to Begin Enrolling Patients in Phase III Study of PROCHIEVE® 8% (progesterone gel) to Reduce Risk of Preterm Birth in Short Cervix Population
Columbia Laboratories, Inc. (NASDAQ: CBRX) has received Institutional Review Board (IRB) approval for the first of 19 planned clinical sites for the Company’s Phase III PREGNANT (PROCHIEVE® Extending GestatioN A New Therapy) study. This randomized, double-blind, placebo-controlled clinical trial will evaluate the effect of PROCHIEVE® 8% on reducing the risk of preterm birth in women with a cervical length between 1.0 and 2.0 centimeters as measured by transvaginal ultrasound at mid-pregnancy.
1/31/2008
Data from Columbia Laboratories’ Study for the Prevention of Preterm Birth to be Presented at the Society for Maternal-Fetal Medicine (SMFM) 2008 Annual Meeting
Columbia Laboratories, Inc. (NASDAQ: CBRX) today announced that data relating to its previously reported prevention of preterm birth trial will be presented in an oral presentation at the SMFM 2008 Annual Meeting held in Dallas, Texas, from January 30, to February 2, 2008. The abstract was published in the 2007 December issue supplement of the American Journal of Obstetrics and Gynecology.